Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

相似書籍

• Brief Report: SWOG S1400D (), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
  由: Aggarwal, Charu, et al.
  出版: (2019)
• SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study)
  由: Edelman, Martin J., et al.
  出版: (2019)
• Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
  由: Herbst, Roy S., et al.
  出版: (2015)
• On the design, conduct and lessons learned from Lung-MAP (SWOG S1400): A biomarker-driven master protocol to evaluate biomarker-driven therapies for previously-treated squamous lung cancer
  由: Redman, Mary W, et al.
  出版: (2020)
• Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
  由: Juric, Dejan, et al.
  出版: (2017)